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Effects of dexamethasone to reverse decreased hepatic midazolam metabolism in 
rats with acute renal failure 
 
Abstract 
1. The inductive effects of dexamethasone on hepatic midazolam metabolism were 
examined in Wistar rats with acute renal failure (ARF) to clarify whether the ARF-
related decrease in the hepatic expression of drug-metabolizing enzymes is caused 
by an impairment in the translation/polypeptide formation process. 
2. ARF was induced with intramuscular glycerol injection. Dexamethasone was 
orally administered. Pooled liver microsomes from 5 rats were prepared with 
ultracentrifugation for each of 4 groups, namely control and ARF rats, control rats 
with dexamethasone treatment, and ARF rats with dexamethasone treatment. 
3. Hepatic drug-metabolizing activity was examined in an incubation study with the 
microsomes, where midazolam was employed as a substrate of cytochrome P450 
(CYP) 3A enzymes. The hepatic protein and mRNA expressions of 
CYP3A23/3A1 and 3A2 enzymes were also evaluated. 
4. With dexamethasone treatment, the hepatic metabolic rate of midazolam increased 
1.4 times in control rats, while it increased 19.6 times in ARF rats, reflecting the 
greater induction of hepatic protein expressions of CYP3A enzymes in ARF rats 
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than in control rats. 
5. The hepatic protein expression process for CYP3A23/3A1 and 3A2 responds well 
to dexamethasone treatment in ARF rats, indicating that the 
translation/polypeptide formation process is not impaired in the presence of ARF. 
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Introduction 
 Hepatic drug metabolism decreases under the influence of impaired renal 
function, as demonstrated with the cytochrome P450 (CYP) 3A substrate midazolam 
(MDZ) in our previous study, in which the hepatic drug-metabolizing activity for MDZ 
decreased in rats with experimentally induced acute renal failure (ARF) as compared 
with control rats (Kusaba et al. 2012). Propagation mechanism by which an influence of 
renal failure reaches the liver is not fully clarified to date, but inflammatory factors 
released into the circulatory system with impaired renal function seem to be partly 
involved in the decreased metabolism (Abdel-Razzak et al., 1995; Assenat et al., 2004; 
Kajikawa et al., 2014). Since the decrease in hepatic drug-metabolizing activity in ARF 
rats is largely due to decreased hepatic protein expression of CYP3A enzymes, it is 
considered that some processes of gene expression, such as transcription and translation, 
are impaired in ARF rats. As the mechanism underlying the decreased enzyme 
expression, a factor influencing the association of nuclear receptors with the promoter 
region of the target gene, such as an alteration of their phosphorylation and/or a 
repression of their translocation, may be responsible for the decrease (Elias et al., 2014; 
Hosseinpour et al., 2007; Krausova et al., 2011; Ourlin et al., 2003). An inhibition of 
ribosomal polypeptide formation could also be a cause of the decrease (Lang et al., 2000). 
In addition to these direct suppressions of translation/polypeptide formation, an altered 
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protein degradation process and a consequent imbalance between protein synthesis and 
degradation may indirectly cause a decrease in protein expression. It was demonstrated 
that the phosphorylation and ubiquitination process of CYP3A enzymes results in a 
reduction of their expression level, largely due to acceleration of their proteasomal 
degradation (Printsev et al., 2017; Wang et al., 2009). However, little has been 
elucidated regarding the mechanism behind the decreased hepatic protein expression of 
drug-metabolizing enzymes in ARF rats. As hepatic drug-metabolizing activity largely 
influences the pharmacokinetics and therapeutic efficacy of various compounds, it is 
worth understanding how the hepatic expression and activity of drug-metabolizing 
enzymes change when homeostasis of the body is impaired by major organ failure. 
 In this study, we conducted examinations to clarify the underlying mechanisms 
of decreased hepatic expressions of CYP3A23/3A1 and 3A2 proteins in ARF rats, with 
a working hypothesis that the translation/polypeptide formation process is inhibited in 
ARF rats. It is reported that ARF is often accompanied with inflammation (Izuwa et al., 
2009), and that inflammatory factors, such as interleukin 1β, suppress the hepatic 
expressions of drug-metabolizing enzymes (Abdel-Razzak et al., 1995; Assenat et al., 
2004). In addition, it was demonstrated that disease model rats showing decreased 
hepatic expression of drug-metabolizing enzymes poorly respond to protein induction 
treatment with the potent protein inducer dexamethasone (Blouin et al., 1993; De Martin 
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et al., 2014; Gabbia et al., 2018). It is therefore considered that dexamethasone induces 
hepatic protein expression of enzymes to a lesser extent in ARF rats than in normal rats, 
since some inhibitory mechanism working behind the translation/polypeptide formation 
process in ARF rats would counteract dexamethasone’s induction process. 
Dexamethasone has been reported to stimulate the hepatic protein expression of CYP3A 
enzymes in a transactivation manner, which is associated with the pregnane X receptor 
to form a heterodimer with the retinoid X receptor, and then the heterodimer binds to the 
response element of the 5’-flanking region of the gene to stimulate protein expression 
(Kishida et al., 2008; Kliewer et al., 1998; Kliewer et al., 2002). If some part of these 
induction processes is impaired in ARF rats, a difference may be observed in 
dexamethasone’s induction effects between normal and ARF rats. With these 
considerations, we performed this study, in which we subjected normal and ARF rats to 
dexamethasone treatment, and then we prepared the liver microsomes to evaluate the 
difference in their hepatic drug-metabolizing activities. We subsequently examined and 
compared the hepatic protein and mRNA expressions of the CYP3A enzymes between 
normal and ARF rats to assess whether an impairment of the translation/polypeptide 
formation process is a cause of the decreased hepatic expression of CYP3A proteins in 
ARF rats. 
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Materials and Methods 
Materials 
 MDZ was purchased from Sandoz (Tokyo, Japan) as a commercially available 
injectable solution in a sterilized isotonic buffer (pH 2.8–3.8). It was used without further 
purification (Hori et al., 2018; Kajikawa et al., 2014). Two MDZ metabolites, 4-
Hydroxy MDZ (4-OH MDZ) and 1’-hydroxy MDZ (1’-OH MDZ), were obtained from 
BD Biosciences (San Jose, CA, USA) and Cerilliant (Round Rock, TX, USA), 
respectively. Dexamethasone was from Tokyo Chemical Industry (Tokyo, Japan). β-
NADPH was from Oriental Yeast (Tokyo, Japan). Glycerol and dimethyl sulfoxide were 
purchased from Wako Pure Chemicals (Osaka, Japan). Purified rabbit polyclonal 
antibody to rat CYP3A23/3A1 (P/N: AB1253) and that to rat CYP3A2 (P/N: AB1276) 
were from Millipore (Billerica, MA, USA) (Kusaba et al., 2012). The primer pairs for 
performing polymerase chain reaction (PCR) and Oligo(dT)20 primer for reverse 
transcription (RT) were obtained via a custom primer synthesis service of 
Invitrogen/Thermo Fisher Scientific (Waltham, MA, USA). The sequences of the primer 
pairs are shown in Table 1. RNase inhibitor was obtained from Nacalai Tesque (Kyoto, 
Japan). All other chemicals were of the finest grade available from local distributers. 
[Table 1] 
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Animals and animal specimen preparation 
 Male Wistar rats at 7 weeks old (190–300 g) were obtained from Japan Charles 
River (Yokohama, Japan). They were caged in an air-conditioned room with controlled 
temperature and relative humidity at 20–25°C and 40–50%, respectively. The light/dark 
cycle was set at 12 hours. All animal experiments were performed in accordance with 
the guidelines for animal experimentation of Okayama University with approval by the 
institutional animal ethics committee (OKU-2013022/OKU-2015421). 
[Figure 1] 
 After a 24-hour acclimatization period, rats were randomly assigned to either 
the control or ARF group. The scheme of animal treatment is shown in Fig. 1. The rats 
in the ARF group were subjected to 24-hour water deprivation, and then they received 
intramuscular injections of 50% glycerol (10 mL/kg) in the left and right thighs to induce 
ARF (Aiba et al., 2006; Kusaba et al., 2012). The rats assigned to the control group 
experienced no water deprivation, and they were injected with saline instead of glycerol. 
After that, rats in both groups were normally fed with free access to water for 24 hours 
until the experiments. The establishment of glycerol-induced ARF was checked based 
on the increased serum creatinine concentration (Kusaba et al., 2012), for which a serum 
specimen was procured before the experiment. The creatinine concentrations in the 
control and ARF rats were 0.37 ± 0.02 and 1.26 ± 0.15 mg/dL, respectively, being 
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significantly different from each other (p<0.05).  
 The dexamethasone treatment to induce hepatic protein expression of the drug-
metabolizing enzymes was performed as follows (Cotreau et al., 2000; Kanazu et al., 
2012). The dexamethasone solution was prepared by dissolving dexamethasone in 
dimethyl sulfoxide at a concentration of 40 mg/mL. This dexamethasone solution was 
orally administered to the control and ARF rats at a dose of 80 mg/kg. The administration 
was performed once a day at 9:00 am for 3 days. 
 Rat liver microsomes were prepared from control rats, ARF rats, and rats that 
received dexamethasone treatment, respectively (Fig. 1). Each of the microsome 
preparations was carried out with excised livers from 5 rats. They were gently diced and 
minced in ice-cold saline to be homogenized together, a part of which was spared for the 
RNA extraction mentioned later, and the microsome preparation was obtained from the 
liver homogenate with conventional ultracentrifugation (Hori et al., 2018; Kusaba et al., 
2012). The protein content of the microsome preparation was measured with the 
Bradford method using the protein assay kit (Bio-Rad, Hercules, CA, USA). The 
preparation was stored at −80°C until being used in the incubation study to evaluate the 
hepatic drug-metabolizing activity and in Western blot analysis to assess hepatic protein 
expressions of CYP3A enzymes. 
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Evaluation of hepatic drug-metabolizing activity in rats  
 The hepatic drug-metabolizing activity was evaluated focusing on CYP3A 
enzymes, in which NADPH-dependent MDZ elimination was examined in incubation 
experiments involving liver microsome preparations as previously reported with slight 
modification (Hori et al., 2018; Kajikawa et al., 2014). In brief, isotonic potassium 
phosphate buffer (pH 7.4) containing 200 µg of the microsomal protein was used as the 
incubation mixture. MDZ was dissolved in the mixture at final concentrations of 1, 2.5, 
5, 7.5, 10, and 20 µM, respectively. Following a 5-min pre-incubation period, 950 µL of 
the incubation mixture was spiked with 50 µL of 20 mM -NADPH solution to start the 
metabolic reaction. The metabolic reaction was allowed to continue for 5 min at 37°C. 
A 200-µL aliquot of the incubation mixture was then quickly transferred into 600 µL of 
ice-cold methanol and vigorously agitated to stop the metabolic reaction. After that, the 
mixture was centrifuged at 10,000×g at 4°C for 3 min to precipitate microsomal protein, 
and then the supernatant was collected for the determination described later. The 
incubation experiments were also carried out without -NADPH, in which potassium 
phosphate buffer was used instead of the -NADPH solution.  
 The elimination rates of MDZ, and the formation rates of its two major 
metabolites, 4-OH MDZ and 1’-OH MDZ, were characterized with the Michaelis-
Menten equation (Eq. 1) (Kajikawa et al., 2014): 
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where v is the -NADPH-dependent elimination rate of MDZ, or the formation rate of 
the metabolite. C is the MDZ concentration in the incubation mixture. Km is the apparent 
Michaelis-Menten constant. Vmax is the maximum MDZ elimination rate, or the 
maximum formation rate of the metabolite. The parameter estimates were calculated 
with the non-linear least square method (Kajikawa et al., 2014). In this study, we 
considered that the MDZ elimination process is accounted for by the drug-metabolizing 
activities of CYP3A23/3A1 and 3A2 proteins, since it was demonstrated that the hepatic 
MDZ metabolism in rats is almost exclusively mediated by those two proteins, where 
the 4-OH MDZ formation is mainly mediated by CYP3A2 protein, while the 1’-OH 
MDZ formation was carried out by both CYP3A23/3A1 and 3A2 proteins (Kobayashi 
et al., 2002; Carr et al., 2006).  
 The hepatic drug-metabolizing activity toward dexamethasone was also 
examined in the incubation experiments with the liver microsomes in a similar manner 
as that for MDZ, in which dexamethasone was applied at a final concentration of 20 µM, 
and 500 µg of microsomal protein was prepared. Following the incubation, the metabolic 
reaction was subjected to vigorous agitation with ice-cold methanol and centrifugation 
for protein precipitation. The resultant supernatant was collected for the determination 
𝑣 =
𝑉max ⋅ 𝐶
𝐾m+ 𝐶
 (1) 
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described later. The NADPH-dependent hepatic metabolism of dexamethasone was 
evaluated by comparing the amount of dexamethasone in the incubation mixture before 
and after the incubation period.  
 
Semi-quantitative evaluation of hepatic protein expression of CYP3A enzymes with 
Western blot analysis 
 The hepatic protein expressions of CYP3A23/3A1 and CYP3A2 were 
evaluated with Western blot analysis in a semi-quantitative manner, as previously 
reported (Hori et al., 2018; Kusaba et al., 2012). The liver microsome preparations were 
diluted with isotonic potassium phosphate buffer to prepare the specimens for 
electrophoresis. A 10-µL specimen was applied to an SDS-polyacrylamide gel (10%) at 
3 µg of microsomal protein/lane. After the electrophoresis, the proteins were transferred 
to a nitrocellulose membrane, and the target proteins were detected with the 
corresponding antibodies to be visualized with the Vectastain® Elite ABC Kit (Vector 
Laboratories, Burlingame, CA, USA) and DAB substrate kit (Vector Laboratories). The 
target band signals were semi-quantitatively evaluated with densitometry.  
 
Evaluation of hepatic mRNA expressions of CYP3A enzymes with real-time RT-PCR 
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 Total RNA extraction from liver tissue was performed with the RNeasy® Mini 
kit (QIAGEN, Germantown, MD, USA) according to the manufacturer’s instructions. 
As the tissue specimen for the kit, the ice-cold liver tissues that were diced and minced 
as mentioned before were finely ground into a paste with a chilled pestle and mortar. A 
total of 30 mg of the paste was supplied for the kit, producing 100 µL of total RNA 
solution. The RNA yield in the solution was evaluated spectrometrically at a wavelength 
of 260 nm. Following total RNA extraction, the RT reaction was performed with the 
Omniscript® RT kit (QIAGEN). In brief, the reaction mixture was prepared with 
Oligo(dT)20 primer and RNase inhibitor, according to the manufacturer’s instructions, 
and then an adequate volume of the total RNA solution was added to the mixture so that 
it contained 2 µg of total RNA. The RT reaction was conducted at 37°C for 60 min. 
After the reverse transcriptase was inactivated by incubating the reaction mixture at 
93°C for 5 min, the mixture was maintained at 4°C until use for the subsequent process. 
 With the reaction mixture obtained in the RT reaction, the hepatic mRNA 
expressions of CYP3A23/3A1 and CYP3A2 enzymes were evaluated by real-time PCR 
employing the THUNDERBIRD® SYBR® qPCR Mix (Toyobo, Osaka). Real-time PCR 
was conducted with the StepOnePlus™ Real-Time PCR System (Applied 
Biosystems/Thermo Fisher Scientific, Waltham, MA, USA). PCR was carried out 
according to the thermal cycle program for amplification with a denaturation step at 
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95°C for 15 seconds, an annealing step at 51°C for 15 seconds, and an extension step at 
72°C for 45 seconds in this order. In the extension step of the amplification cycle, the 
fluorescence was measured with normalization based on fluorescence coming from the 
internal standard dye ROX. The threshold cycle number was determined as the earliest 
cycle number at which the fluorescence started to increase in a log-linear manner. The 
mRNA expressions of Cyp3a23/3a1 and Cyp3a2 were evaluated relative to those of 
Gapdh, and they were expressed with their common logarithms.  
 
Analytical methods 
 MDZ and its metabolites, 4-OH MDZ and 1’-OH MDZ, were simultaneously 
determined by HPLC equipped with an octadecyl silica column (3 µm, 4.6×150 mm, 
InertSustain® C18, GL Science, Tokyo, Japan) (Hori et al., 2018; Kajikawa et al., 2014). 
Dexamethasone was determined in the same manner as that for MDZ. The 
aforementioned supernatant specimen obtained in the incubation experiment with the 
liver microsomes was filtered with a nylon membrane syringe filter (0.2-µm pore size, 
Advanced Microdevices, Ambala Cantt, India). The filtered specimen was subjected to 
HPLC for determination. MDZ, its two metabolites, and dexamethasone were eluted 
with a mobile phase containing 40% methanol and 60% sodium phosphate buffer (10 
mM, pH 3.1). They were detected spectrophotometrically at a wavelength of 229 nm.  
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Data analysis  
 Data are expressed as the mean ± S.E. The significance of differences between 
two values was evaluated by Student’s t-test, and p<0.01 was considered significant.  
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Results 
Evaluation of dexamethasone-induced increase in hepatic MDZ metabolism in ARF rats 
 First, the hepatic drug-metabolizing activity was examined with MDZ in liver 
microsomes prepared from control rats, ARF rats, and rats that underwent 
dexamethasone treatment. Regarding MDZ metabolism without dexamethasone 
treatment, it was shown as expected that the MDZ-metabolizing activity in ARF rats was 
noticeably lower than that in control rats (Fig. 2A and 2C). As for the dexamethasone-
induced increase in MDZ metabolism, besides control rats (Fig. 2A and 2B), the 
treatment increased hepatic MDZ metabolism in ARF rats (Fig. 2C and 2D), and the 
extent of increase in ARF rats was larger than that in control rats (Fig. 2B and 2D). With 
calculation of the Michaelis-Menten parameters for MDZ elimination, the Vmax value 
increased by 1.4 times with dexamethasone treatment in control rats, while it increased 
by 19.6 times with treatment in ARF rats (Table 2). A greater increase in the Vmax value 
was shown in a corresponding manner for metabolite formation. That is, with 
dexamethasone treatment, the value for 4-OH MDZ formation increased by 1.7 times in 
control rats, while it increased by 62.8 times in ARF rats (Table 2). In the case of 1’-OH 
MDZ formation, the values in control and ARF rats increased by 1.9 and 24.7 times, 
respectively. For MDZ metabolism in ARF rats, a change in Km values was also 
observed with dexamethasone treatment (Table 2), suggesting that the hepatic 
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expressions of CYP3A23/3A1 and 3A2 proteins were induced in an imbalanced manner. 
[Figure 2] 
[Table 2] 
 
Evaluation of hepatic drug-metabolizing activity toward dexamethasone in ARF rats 
 It was considered that the ARF-related decrease in hepatic drug metabolism 
also affects dexamethasone metabolism, so that dexamethasone used for the treatment 
could differently accumulate in control and ARF rats. To examine this possibility, the 
hepatic drug-metabolizing activity toward dexamethasone was evaluated in control and 
ARF rats. As a result, it was shown that the dexamethasone elimination rate in ARF rats 
was markedly decreased to 48.5% of that in control rats (Fig. 3), indicating that the ARF 
rats were exposed to about two times more dexamethasone compared with the control 
rats.  
[Figure 3] 
 
Evaluation of dexamethasone-induced increase in hepatic protein expression of CYP3A 
enzymes in ARF rats 
 Since the observed increase in hepatic MDZ-metabolizing activity with 
dexamethasone treatment was considered to be related to an increase in hepatic 
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expression of drug-metabolizing enzymes, we subsequently evaluated the hepatic 
expressions of CYP3A23/3A1 and 3A2 proteins. They are known to largely contribute 
to MDZ metabolism in rats. As shown in Fig. 4, the hepatic expressions of 
CYP3A23/3A1 and CYP3A2 proteins that decrease or tend to decrease in ARF rats 
noticeably increased with dexamethasone treatment. In addition, the induction effects of 
dexamethasone were greater in ARF rats than control rats. That is, the CYP3A23/3A1 
expression increased by 21% in control rats, while it increased by 90% in ARF rats (Fig. 
4A). In the case of CYP3A2 expression, although it increased by 4.6 times with 
dexamethasone treatment in ARF rats, it showed a slightly non-statistically significant 
decrease in control rats (Fig. 4B).  
[Figure 4] 
 
Evaluation of dexamethasone-induced increase in hepatic mRNA expression of CYP3A 
enzymes in ARF rats 
 The effects of dexamethasone treatment on the hepatic mRNA expression of 
Cyp3q23/3a1 and Cyp3a2 were also examined. Hepatic mRNA expression of 
Cyp3a23/3a1 markedly increased with dexamethasone treatment in control and ARF rats, 
and the extent of the increase was similar between the two groups. (Fig. 5A). As for the 
expression of Cyp3a2, dexamethasone decreased mRNA expression in control and ARF 
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rats, in contrast to the expression of Cyp3a23/3a1 (Fig. 5B). In addition, the observed 
decrease in the mRNA expression of Cyp3a2 in ARF rats is inconsistent with the fact 
that dexamethasone increases protein expression of CYP3A2 in ARF rats (Fig. 4B). 
[Figure 5] 
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Discussion 
 It is well-known that hepatic drug-metabolizing activity is affected by an 
impaired renal function, as exemplified by the fact that hepatic MDZ metabolism 
decreases in ARF rats (Kusaba et al., 2012), while little is known about the mechanism 
underlying the decrease. In this study, we examined hepatic drug metabolism in ARF 
rats with a working hypothesis that the translation/polypeptide formation process of 
hepatic drug-metabolizing enzymes, such as CYP3A proteins, is impaired with renal 
failure. It is rational to consider that if the translation/polypeptide formation process is 
impaired, hepatic protein expression will not be stimulated by chemical inducers, such 
as dexamethasone. In fact, a decrease in hepatic drug-metabolizing activity in the 
presence of ineffectiveness of dexamethasone treatment was demonstrated in Zucker 
fatty rats, an animal model of diabetes (Blouin et al., 1993). 
 Prior to the study with dexamethasone treatment, we examined hepatic MDZ 
metabolism in ARF rats to confirm that the hepatic drug-metabolizing activity decreased 
with renal failure. As a result, the hepatic MDZ-metabolizing activity decreased in ARF 
rats (Fig. 2A and 2C), and the Michaelis-Menten parameters in ARF rats were noticeably 
different from those in control rats (Table 2). As for the effect of dexamethasone 
treatment, the hepatic MDZ-metabolizing activity was shown to increase in control rats 
with dexamethasone treatment (Fig. 2B). On the other hand, it was an unexpected 
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finding that the hepatic MDZ-metabolizing activity in ARF rats also increased with 
dexamethasone treatment (Fig. 2D). The observation that dexamethasone induces the 
hepatic drug-metabolizing activity in ARF rats as if there were little interference with 
the induction suggests that the translation/polypeptide formation process of the enzymes 
is not impaired in ARF rats. The results of Western blot analysis support these findings. 
As shown in Fig. 4, the hepatic protein expressions of CYP3A23/3A1 and CYP3A2 both 
increased in ARF rats with dexamethasone treatment. It was also shown that their hepatic 
mRNA expressions measured before the treatment were not different in control and ARF 
rats (Fig. 5). It is therefore probable that while the decrease in the hepatic MDZ 
metabolism is caused by a decrease in the hepatic protein expression of CYP3A enzymes 
in ARF rats, the cause of the decreased protein expression is not related to an impairment 
of the translation/polypeptide formation process of the enzymes. The process may be 
intact regarding the responsiveness to dexamethasone treatment.  
 Although the mechanism underlying the decreased hepatic protein expression 
of CYP3A enzymes in ARF rats has not been fully elucidated, it can be speculated based 
on the findings in this study. Besides the fact that the decreased hepatic protein 
expression in ARF rats is more definitive for CYP3A2 than that for CYP3A23/3A1 (Fig. 
4), it is intriguing that while the protein expression of CYP3A2 largely decreases in ARF 
rats (Fig. 4B), its mRNA expression is not influenced (Fig. 5B). This may be explained 
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by the fact that the CYP3A proteins are subjected to ubiquitin-dependent proteasomal 
degradation (Printsev et al., 2017; Wang et al., 1999; Wang et al., 2009). That is, the 
degradation of CYP3A proteins may be facilitated in ARF rats. It was reported that if 
the phosphorylation sites in the amino acid sequence of CYP3A protein are 
phosphorylated to a greater extent, it would be associated with ubiquitin at a faster rate 
to be degraded (Wang et al., 2009). Therefore, it is rational to consider that the 
phosphorylation process of CYP3A proteins is stimulated, and/or a suppression of 
ubiquitin-dependent proteasomal degradation is inhibited in ARF rats. Although growth 
hormone is known to be involved in the gene expression of CYP3A proteins (Dhir et al., 
2003; Li et al., 2015), it is unlikely that the secretion of growth hormone decreases in 
ARF rats, as the hepatic mRNA expressions of Cyp3a23/3a1 and Cyp3a2 were little 
affected in ARF rats (Fig. 5).  
 It is also interesting that the extent of the dexamethasone-induced increase in 
the MDZ-metabolizing activity of ARF rats was much greater than that in control rats 
(Fig. 2B and 2D). It may be necessary to consider that the decreased hepatic drug-
metabolizing activity in ARF rats influences the pharmacokinetics of dexamethasone. 
That is, the hepatic drug-metabolizing activity for dexamethasone in ARF rats decreases 
to about a half of that in control rats (Fig. 3), meaning that ARF rats in the 
dexamethasone treatment group receive two times more dexamethasone than control rats. 
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However, even if this is taken into account, it may still be difficult to fully explain the 
difference in the extents of increase in the MDZ-metabolizing activity between control 
and ARF rats (Fig. 2). It was shown that the MDZ elimination rate measured at a 
substrate concentration of 20 µM increases by 13.3 times with dexamethasone treatment 
in ARF rats (0.79 versus 10.56 nmol/min/mg of microsomal protein) (Fig. 2C and 2D), 
while the rate increases by 1.5 times in control rats (3.46 versus 5.30 nmol/min/mg of 
microsomal protein) (Fig. 2A and 2B). Therefore, the inductive effect of dexamethasone 
on hepatic drug-metabolizing activity may be more potently exerted in ARF rats than in 
control rats.  
 The potentiation of the effect of dexamethasone may be reflected by an 
increased hepatic protein expression of CYP3A enzymes. As shown in Fig. 4, 
dexamethasone treatment increased the protein expressions of CYP3A enzymes to a 
greater extent in ARF rats than in control rats. However, regarding the mRNA expression, 
the dexamethasone-induced increase in ARF rats was similar to that in control rats (Fig. 
5). These results suggest that the potentiation of the dexamethasone effect in ARF rats 
is also related to a change in the protein degradation process. It was reported that a 
suppression of the degradation of CYP3A protein results in an apparent increase in its 
protein expression (Printsev et al., 2017; Santoh et al., 2016), but we could not provide 
concrete evidence to prove that this reported finding is applicable to our findings in this 
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study. For future studies, we hypothesized that dexamethasone promotes a suppression 
process that counteracts the degradation process of CYP3A proteins, probably by 
modulating phosphorylation and/or dephosphorylation processes of the proteins. It is 
also likely that dexamethasone alters the substrate affinity regarding protein degradation 
process, and an altered affinity may contribute to weakening the ARF-related inhibition 
of the suppression process as well. 
 We additionally observed a dissimilarity between CYP3A23/3A1 and CYP3A2 
regarding the gene expression and responsiveness to dexamethasone treatment. 
Regarding their difference in responsiveness to dexamethasone treatment, the gene 
expression of Cyp3a2 is known to be less induced by dexamethasone as compared with 
that of Cyp3a23/3a1, partly due to a slight difference in their nucleotide sequences in 
the proximal 5’-flanking region (Huss and Kasper, 1998). It was also reported that 
dexamethasone induces the gene expression of the nuclear receptor RXR in rats (Li et 
al., 2015). RXR suppresses the gene expression of CYP3A proteins (Steineger et al., 
1998). Based on these things, dexamethasone may act on mRNA expression of Cyp3a2 
not in an increasing, but in a decreasing manner (Fig. 5). A dissimilarity regarding the 
gene and protein expression between CYP3A23/3A1 and CYP3A2 enzymes was also 
reported in cholestatic rats, in which dexamethasone was reported to exert its inductive 
effect via an activation of the nuclear receptor CAR (Gabbia et al., 2018). However, the 
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potentiation of the dexamethasone effect was not observed in the animal model, 
suggesting that the mechanism underlying the dissimilarity in cholestatic rats is different 
from that in ARF rats we observed. As for the relationship between mRNA and protein 
expressions, an increase in the protein expression of CYP3A23/3A1 may follow an 
increase in mRNA expression (Figs. 4A and 5A), but this is not the case for CYP3A2 
expression (Figs. 4B and 5B). This may reflect the difference in their processes for 
regulating gene expression. It has been demonstrated that the gene expression of 
Cyp3a23/3a1 is regulated by microRNA, miR-23b (Sun et al., 2016), while it is still 
unknown whether this is also the case for Cyp3a2 expression. It is probable that the 
expression level of CYP3A23/3A1 protein is determined by regulating its mRNA 
expression, and that of CYP3A2 protein is managed by the protein degradation process.  
 In this study, we demonstrated with dexamethasone treatment that although the 
hepatic MDZ-metabolizing activity decreases in ARF rats due to a decrease in hepatic 
protein expression of CYP3A proteins, the translation/polypeptide formation process of 
CYP3A proteins is not impaired in ARF rats. Besides the protein expression process, an 
alteration of the protein degradation process may be involved in the decreased hepatic 
protein expression in ARF rats. 
–26– 
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Legends to Figures 
Fig. 1. Animal treatment scheme in this study. Twenty male Wistar rats were randomly 
and evenly assigned to either the control or ARF group. Ten rats in the ARF 
group were subjected to the glycerol injection to induce ARF, and 10 rats in the 
control group received saline injection. Then, 5 rats in the control group and 5 
rats in the ARF groups were orally treated with dexamethasone at a dose of 80 
mg/kg for 3 days. The other rats in both groups were normally fed without 
receiving any substitutive treatment. After that, rats were sacrificed and livers 
were excised. 
 
Fig. 2. Evaluation of the dexamethasone-induced increase in hepatic MDZ 
metabolism in control and ARF rats. The MDZ metabolism was examined with 
liver microsomes, and the elimination rate of MDZ was evaluated along with 
the formation rates of its two metabolites, 4-OH and 1’-OH MDZ. In panel A, 
the elimination and formation profiles of MDZ metabolism in control rats 
without dexamethasone treatment are shown. Those profiles in control rats 
with dexamethasone treatment are presented in panel B. The profiles in ARF 
rats without dexamethasone treatment are shown in panel C, and those in ARF 
rats with the treatment are indicated in panel D. In all panels, the elimination 
–35– 
profiles of MDZ are indicated with open circles, while the formation profiles 
of 4-OH and 1’-OH MDZ are shown with open and closed squares, respectively. 
Data are expressed as the mean ± S.E. from 4–5 independent experiments. 
Some error bars are behind the symbols. Solid lines are the best-fit lines for the 
corresponding values obtained with the Michaelis-Menten equation, being 
applied to characterize the profiles.  
 
Fig. 3. Hepatic metabolism of dexamethasone in control and ARF rats. The NADPH-
dependent elimination rates of dexamethasone were examined with liver 
microsomes from control and ARF rats, in which dexamethasone was used at 
a concentration of 20 µM. Data are expressed as the mean ± S.E. from 6 
independent experiments. *p<0.01: significantly different between the values. 
 
Fig. 4. Induction effects of dexamethasone on the hepatic protein expressions of 
CYP3A23/3A1 (panel A) and 3A2 (panel B) in control and ARF rats. In both 
panels, two representative results given in Western blotting performed with 
anti-CYP3A23/3A1 and 3A2 antibodies are presented above the corresponding 
bar graph. Data are expressed as the mean ± S.E. from 4 independent 
experiments. *p<0.01: significantly different between the values with and 
–36– 
without dexamethasone treatment in the corresponding group. #p<0.01: 
significantly different from the value in the control rats without dexamethasone 
treatment. Keys: w/o DEX, without dexamethasone treatment; w/ DEX, with 
dexamethasone treatment; DEX, dexamethasone.  
 
Fig. 5. Effects of dexamethasone treatment on hepatic mRNA expression of 
Cyp3a23/3a1 (panel A) and Cyp3a2 (panel B) in control and ARF rats. In both 
panels, the mRNA expression level of the CYP3A enzyme was evaluated 
relative to that of Gapdh. The obtained value is expressed using a common 
logarithmic scale. Data are expressed as the mean ± S.E. from 5–6 independent 
experiments. *p<0.01: significantly different between the values with and 
without dexamethasone treatment in the corresponding group. Keys: w/o DEX, 
without dexamethasone treatment; w/ DEX, with dexamethasone treatment; 
DEX, dexamethasone.  
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Tables 
Table 1. Primer pairs used for PCR amplification to evaluate hepatic mRNA expression of drug-metabolizing enzymes in rats. 
 mRNA Forward primer Reverse primer Location Amplicon size Reference 
  Cyp3a23/3a1 5’-gga gat cac agc cca gtc aat c-3’ 5’-tgg cca gtg ctg tgg atc ac-3’ 955–1303 349 bp Matsubara et al., 2004 
  Cyp3a2 5’-ttg atc cgt tgt tct tgt ca-3’ 5’-ggc cag gaa ata caa gac aa-3’ 713–1035 323 bp Wonganan et al., 2009 
  Gapdh 5’-gtt acc agg gct gcc ttc tc-3’ 5’-ggg ttt ccc gtt gat gac c-3’ 121–288 168 bp Naruhashi et al., 2002 
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Table 2. Michaelis-Menten parameters for MDZ metabolism determined in liver microsomes prepared from control and ARF rats  
with (w/) and without (w/o) dexamethasone treatment. a 
  Control rats ARF rats 
  w/o dexamethasone w/ dexamethasone w/o dexamethasone w/ dexamethasone 
  Vmax b Km c Vmax b Km c Vmax b Km c Vmax b Km c 
Elimination rate 
 MDZ 4.50 ± 0.28 5.28 ± 0.75 6.42 ± 0.35 d 4.50 ± 0.67 0.90 ± 0.10 e 2.08 ± 0.38 e 17.60 ± 1.08 d 12.08 ± 1.38 d 
Formation rates of metabolites 
 4-OH MDZ 2.47 ± 0.20 3.08 ± 0.81 4.38 ± 0.45 d 5.18 ± 1.04 0.37 ± 0.02 e 1.80 ± 0.60 e 23.23 ± 4.90 d 50.10 ± 13.24 d 
 1’-OH MDZ 0.58 ± 0.04 3.21 ± 0.61 1.12 ± 0.12 d 1.68 ± 0.58 0.15 ± 0.02 e 6.13 ± 1.20 3.70 ± 0.50 d 10.66 ± 2.77 
a Data are shown as the mean ± S.E. from 4–5 independent experiments. 
b Data are expressed in units of nmol/min/mg of microsome protein. 
c Data are expressed in units of µM. 
d p<0.01, significantly different between the values with and without dexamethasone treatment in the corresponding animal group. 
e p<0.01, significantly different from the corresponding value in the control rats. 
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